Evolus

Yahoo Finance • 24 days ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

NEWPORT BEACH, Calif., September 08, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell a... Full story

Yahoo Finance • 2 months ago

What's going on in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 86.14% SAF... Full story

Yahoo Finance • 2 months ago

Here are the top movers in Wednesday's session.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GO [https://www.cha... Full story

Yahoo Finance • 2 months ago

The market is filled with gapping stocks in Wednesday's session.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX... Full story

Yahoo Finance • 2 months ago

Discover the top movers in Wednesday's pre-market session.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story

Yahoo Finance • 2 months ago

Evolus outlines $700M 2028 revenue target and cost realignment amid market softness

Earnings Call Insights: Evolus, Inc. (EOLS) Q2 2025 MANAGEMENT VIEW * CEO David Moatazedi reported that "our second quarter results came in below expectations, reflecting one of the most challenging market environments we've seen in re... Full story

Yahoo Finance • 2 months ago

Top movers in Tuesday's after hours session

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 2 months ago

Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M

* Evolus press release [https://seekingalpha.com/pr/20190054-evolus-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:EOLS [https://seekingalpha.com/symbol/EOLS]): Q2 GAAP EPS of -$0.27 misses by $0.07.... Full story

Yahoo Finance • 2 months ago

Jeuveau shows fast onset and long duration in neurotoxin study

NEWPORT BEACH, Calif. - A landmark independent study published in JAMA Dermatology has directly compared four FDA-approved botulinum toxin products for treating glabellar lines, finding that Jeuveau (prabotulinumtoxinA-xvfs) demonstrated f... Full story

Yahoo Finance • last year

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 2 years ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story

Yahoo Finance • 2 years ago

"Extra-Strength" 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

"Extra-strength" 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment 40U results indicate a similar safety p... Full story

Yahoo Finance • 3 years ago

Q4 2022 Evolus Inc Earnings Call

Participants David Moatazedi; President, CEO & Director; Evolus, Inc. David K. Erickson; VP of IR; Evolus, Inc. Rui Avelar; Chief Medical Officer and Head of Research & Development; Evolus, Inc. Sandra Beaver; CFO; Evolus, Inc. Annabe... Full story

Yahoo Finance • 3 years ago

Evolus to Participate in the Barclays Global Healthcare Conference

NEWPORT BEACH, Calif., February 28, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its manageme... Full story

Yahoo Finance • 3 years ago

Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress

Oral presentation for longer duration formulation on Saturday, January 28, 2023 Investor webcast to discuss findings on Monday, January 30, 2023 NEWPORT BEACH, Calif., January 23, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a perf... Full story

Yahoo Finance • 3 years ago

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

Results demonstrated percentages of male responders treated with Jeuveau® achieved approximately 10% higher results across all visits NEWPORT BEACH, Calif., August 24, 2022--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beau... Full story

Yahoo Finance • 3 years ago

Evolus Reports First Quarter 2022 Results and Provides Business Update

Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million Reiterating Full-Year non-GAAP Operating Expense Guidance Strong Cash Position of $106.7 Million Expe... Full story

Yahoo Finance • 3 years ago

Kaskela Law LLC Announces Stockholder Investigation of Evolus, Inc. (EOLS) and Encourages Long-Term EOLS Stockholders to Contact the Firm

PHILADELPHIA, April 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) on behalf of the Company’s long-term shareholders. Evolus stockholders who purch... Full story

Yahoo Finance • 4 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evolus, Inc. (NASDAQ: EOLS) and Encourages Long-Term EOLS Shareholders to Contact the Firm

PHILADELPHIA, March 29, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) on behalf of the Company’s long-term shareholders. Recently an amended securitie... Full story